Key facts
- This page summarizes George Migausky V's Form 4 filing for Immunovant, Inc. (IMVT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Apr 2025, 16:39.
George Migausky V - 01 Apr 2025 Form 4 Insider Report for Immunovant, Inc. (IMVT)
- Reporting relationship
- Director
- Issuer ticker
- IMVT
- Reported as of
- 01 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Apr 2025, 16:39:53 UTC
- Prior SEC filing
- 04 Jun 2024
- Next SEC filing
- 03 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eva Renee Barnett, attorney-in-fact for George V. Migausky
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
George Migausky V filed Form 4 for Immunovant, Inc. (IMVT) on 03 Apr 2025.
Change
- Previous filing in this sequence was filed on 04 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
IMVT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +16,188
- Change %
- +13%
- Price
- $0.000000
- Shares after
- 137,251
- Date
- 01 Apr 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMVT
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +7,600
- Change %
- Price
- $0.000000
- Shares after
- 7,600
- Date
- 01 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 7,600
- Exercise price
- $15.20
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
Footnote F2
The shares underlying the options will vest on April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date.